Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRO-CD7 CAR-NK cells
- Development stage
- Preclinical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CRO-CD7 CAR-NK cells are an engineered cell therapy derived from human pluripotent stem cells where the CD7 gene is knocked out and a CD7-specific chimeric antigen receptor (CAR) is introduced, followed by overexpression of the CXCR4 chemokine receptor. The knockout of CD7 prevents cellular fratricide during manufacturing and application, as CD7 is expressed on both normal and malignant NK/T cells. CXCR4 overexpression enhances cell homing to bone marrow and tissue persistence. These cells are differentiated into induced NK cells (iNKs) and used as an adoptive cell therapy to target CD7-positive T-cell malignancies, notably T-cell acute lymphoblastic leukemia (T-ALL). The approach enables large-scale generation of fratricide-resistant, highly potent CAR-NK cells with improved anti-tumor efficacy in vivo[1][3].
- Brand names
- CRO-CD7 CAR-NK cellsCRO-CD-7 CAR-NK cellsCRO-CD 7 CAR-NK cells
- Other names
- CRO-CD7 CAR-iNK cellsCRO-CD-7 CAR-iNK cellsCRO-CD 7 CAR-iNK cells
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)CD7 (CD7 antigen)
Beyond the preview
Go deeper on CRO-CD7 CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRO-CD7 CAR-NK cells.